-
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
van Lierop, Z. Y. G., Wieske, L., Koel-Simmelink, M. J. A., Chatterjee, M., Dekker, I., Leurs, C. E., Willemse, E. A. J., Moraal, B., Barkhof, F., Eftimov, F., Uitdehaag, B. M. J., Killestein, J. & Teunissen, C. E., Jan 2022, In: Multiple sclerosis (Houndmills, Basingstoke, England). 28, 1, p. 102-110 9 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms: End of natalizumab cycle, recurrence of MS symptoms
van Kempen, Z. L. E., Doesburg, D., Dekker, I., Lissenberg-Witte, B. I., de Vries, A., Claessen, I. A., Brinke, A. T., Rispens, T. & Killestein, J., 22 Oct 2019, In: Neurology. 93, 17, p. e1579-e1586Research output: Contribution to journal › Article* › Academic › peer-review
-
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
Leurs, C. E., van Kempen, Z. L. E., Dekker, I., Balk, L. J., Wattjes, M. P., Rispens, T., Uitdehaag, B. M. J. & Killestein, J., Oct 2018, In: Multiple sclerosis (Houndmills, Basingstoke, England). 24, 11, p. 1453-1460Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
